Victory Capital Management Inc. Purchases 2,632 Shares of Guardant Health, Inc. (NASDAQ:GH)

Victory Capital Management Inc. grew its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 21.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,048 shares of the company’s stock after acquiring an additional 2,632 shares during the period. Victory Capital Management Inc.’s holdings in Guardant Health were worth $407,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Beck Bode LLC bought a new position in shares of Guardant Health in the fourth quarter valued at approximately $3,861,000. Van ECK Associates Corp lifted its stake in Guardant Health by 29.4% during the 4th quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock valued at $73,000 after acquiring an additional 614 shares in the last quarter. Headlands Technologies LLC boosted its holdings in Guardant Health by 362.3% during the 4th quarter. Headlands Technologies LLC now owns 2,353 shares of the company’s stock worth $64,000 after acquiring an additional 1,844 shares during the last quarter. Truist Financial Corp bought a new stake in shares of Guardant Health in the 4th quarter worth $258,000. Finally, State of New Jersey Common Pension Fund D raised its holdings in shares of Guardant Health by 53.5% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 100,948 shares of the company’s stock valued at $2,731,000 after purchasing an additional 35,202 shares during the last quarter. 92.60% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the company. The Goldman Sachs Group decreased their price target on Guardant Health from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, April 15th. Guggenheim restated a “neutral” rating on shares of Guardant Health in a research report on Friday, April 5th. Craig Hallum initiated coverage on shares of Guardant Health in a research report on Wednesday, April 24th. They issued a “buy” rating and a $28.00 price objective on the stock. Piper Sandler reduced their target price on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating for the company in a research report on Monday, February 26th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, Guardant Health has an average rating of “Moderate Buy” and an average price target of $36.60.

Insider Activity at Guardant Health

In other news, insider Kumud Kalia purchased 2,187 shares of the stock in a transaction on Monday, March 18th. The shares were acquired at an average price of $17.82 per share, with a total value of $38,972.34. Following the completion of the acquisition, the insider now directly owns 12,722 shares of the company’s stock, valued at $226,706.04. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.20% of the stock is currently owned by corporate insiders.

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $25.52 on Friday. The firm’s 50 day moving average price is $19.55 and its 200-day moving average price is $22.20. The company has a quick ratio of 5.66, a current ratio of 5.95 and a debt-to-equity ratio of 16.70. The stock has a market capitalization of $3.12 billion, a PE ratio of -6.51 and a beta of 0.92. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $41.06.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.65). Guardant Health had a negative return on equity of 246.47% and a negative net margin of 76.34%. The company had revenue of $155.05 million during the quarter, compared to analysts’ expectations of $151.71 million. Equities research analysts expect that Guardant Health, Inc. will post -3.49 EPS for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.